Acrivon Therapeutics announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ACR-2316, the company’s internally discovered, potent, selective WEE1/PKMYT1 inhibitor, designed by AP3 to overcome the limitations of single-target WEE1 and PKMYT1 inhibitors. ACR-2316 is initially being developed in selected solid tumors identified by AP3.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics price target raised to $28 from $25 at BMO Capital
- Acrivon Therapeutics: Promising Trial Results and FDA Clearance
- Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg
- Acrivon Therapeutics upgraded to Buy from Neutral at Ladenburg
- Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study